Avsnitt
-
1in 7 US adults are estimated to have chronic kidney disease, or CKD. Because early stages of the disease are often clinically silent, 90% of individuals with CKD don’t know they have it. This podcast highlights the importance of early CKD detection and the need for proper screening, especially in individuals with hypertension and diabetes. The Kidney Profile aligns with guidelines and includes the urine-albumin-creatinine ratio and eGFR. The new 2024 guidelines recommend using both creatinine and Cystatin C in estimating eGFR in certain populations, which provides a more accurate risk assessment for CKD and other cardiometabolic conditions like heart disease and stroke. By adopting this dual approach, healthcare providers can improve early detection, staging, and management of CKD, leading to better patient outcomes.
Learning Objectives:
Understand the role of the Kidney Profile in CKD diagnosis and how it aligns with the 2024 KDIGO guidelines. (1:40, 5:15)Identify at-risk populations for CKD, including those with hypertension and diabetes, and understand the importance of early screening and management. (1:30)Learn how combining creatinine and cystatin C in eGFR improves the prediction of CKD progression and associated cardiometabolic risks. (4:30)To learn more, please review the additional resources below for information on our cardiovascular, metabolic, endocrine, and wellness offerings, as well as educational resources and insights from our team of experts. At Quest Diagnostics, we are committed to providing you with results and insights to support your clinical decisions.
Date: 12/2024
Contributor(s): Dr. Maeson Latsko
Additional Resources:
Quest Diagnostics Clinical Education Center [Link]
Ordering information:
Kidney Profile [link]
Kidney Profile Test Summary [link]
eGFR with Creatinine and Cystatin C [link]
References:
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117-S314. doi:10.1016/j.kint.2023.10.018
National Kidney Foundation. Kidney Disease: Fact Sheet. National Kidney Foundation. August 6, 2024. Accessed December 19, 2024. https://www.kidney.org/about/kidney-disease-fact-sheet
-
Increased rates of obesity and type 2 diabetes are increasing rates of cardiometabolic conditions. Identifying and intervening in early stages of metabolic dysfunction is crucial in order to delay and prevent disease progression. The Metabolic Risk Panel is a comprehensive test that helps identify individuals at risk for metabolic dysfunction, insulin resistance, and cardiovascular disease. The panel includes Hemoglobin A1C, Insulin Resistance Panel with Score, Lipid Panel, and Apolipoprotein B (apoB), which together provide a more detailed picture of cardiometabolic health than traditional tests alone. By incorporating these biomarkers, clinicians can detect metabolic risks earlier, enabling proactive interventions to prevent conditions like Type 2 Diabetes, Cardiovascular Disease, and other related cardiometabolic conditions.
Learning Objectives:
Understand the components of the Metabolic Risk Panel, including Hemoglobin A1C, insulin resistance panel with score, lipid panel, and Apolipoprotein B, and how they improve risk assessment. (0:33)Explain the role of insulin resistance in the development of metabolic dysfunction and its connection to early signs of type 2 diabetes. (2:25)Recognize the importance of apolipoprotein B (apoB) in evaluating lipid metabolism and its role in cardiovascular risk assessment, especially in patients with insulin resistance or metabolic syndrome. (3:15)Identify how combining traditional and advanced biomarkers in the Metabolic Risk Panel helps clinicians catch metabolic and cardiovascular risks early, enabling more effective prevention and management. (4:30)To learn more, please review the additional resources below for information on our cardiovascular, metabolic, endocrine, and wellness offerings, as well as educational resources and insights from our team of experts. At Quest Diagnostics, we are committed to providing you with results and insights to support your clinical decisions.
Date: 12/2024
Contributor(s): Dr Maeson Latsko
Additional Resources:
Quest Diagnostics Clinical Education Center [Link]
Ordering information:
Metabolic Risk Panel [link]
References:
Cannon A, Handelsman Y, Heile M, Shannon M. Burden of illness in type 2 diabetes mellitus. J Manag Care Spec Pharm. 2018;24(9-a Suppl):S5-S13. doi:10.18553/jmcp.2018.24.9-a.s5
Johannesen CDL, Langsted A, Nordestgaard BG, Mortensen MB. Excess apolipoprotein B and cardiovascular risk in women and men. J Am Coll Cardiol. 2024;83(23):2262-2273. doi:10.1016/j.jacc.2024.03.423
Centers of Medicare & Medicaid Services. Diabetes Screening & Definitions Update: CY 2024 physician fee schedule final rule. June 25, 2024. Accessed December 19, 2024. https://www.cms.gov/files/document/mm13487-diabetes-screening-definitions-update-cy-2024-physician-fee-schedule-final-rule.pdf
Centers for Disease Control and Prevention. (2017). National diabetes statistics report, 2017: Estimates of Diabetes and its Burden in the United States. Retrieved from https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf
-
Saknas det avsnitt?
-
Identifying insulin resistance offers significant—and often untapped—clinical value and can help healthcare providers and their patients take action with diet and lifestyle choices to avoid or change the progression to prediabetes and diabetes. Today’s episode features Patty Bianchi, Registered Dietitian Nutritionist and Certified Diabetes Care and Education Specialist and Trisha Winchester, PhD, Quest Diagnostics Sr Manager for Clinical & Education.
This episode will
Review glucose regulation by insulin (1:15) Discuss how insulin resistance is measured (3:00) Review actionable ways to reduce insulin resistance through lifestyle (4:00), exercise (6:30), diet (8:50), stress and sleep (11:50)Discuss the 4myheart patient education program offered through Quest Diagnostics Center of Excellence at Cleveland Heartlab (14:30)To learn more, please review the additional resources below for information on our cardiovascular, metabolic, endocrine, and wellness offerings, as well as educational resources and insights from our team of experts. At Quest Diagnostics, we are committed to providing you with results and insights to support your clinical decisions.
Date: 11/2024
Contributor(s): Patty Bianchi, Trisha Winchester, PhD
Additional Resources:
Podcast: The Insulin Resistance Revolution: The Key to Preventing Chronic Conditions (17 min)
Webinar: Early Identification of Type 2 Diabetes Risk for the Primary Care Setting
Ordering information:
Insulin Resistance Panel with Score | Test Detail | Quest Diagnostics
Insulin Resistance Panel with Score | Test Summary | Quest Diagnostics
-
Metabolic dysfunction is a common root cause of many cardiometabolic conditions that burden the healthcare system. This episode will address insulin resistance, a syndrome that underlies metabolic dysfunction, and how tools can catch risk early, allowing actions that may prevent and reverse the onset of chronic illness. Today’s episode is with Quest Diagnostics experts Kenneth French, Senior Clinical Consultant, and Dr Maeson Latsko, clinical and education specialist.
This episode will
Identify how early identification of insulin resistance can prevent the rise in metabolic dysfunction and Type II Diabetes (3:00)Describe the insulin resistance panel with score (8:11) Elucidate how identifying insulin resistance can prevent other chronic illness, such as liver related disorders and kidney disease (12:41)To learn more, please review the additional resources below for information on our cardiovascular, metabolic, endocrine, and wellness offerings, as well as educational resources and insights from our team of experts. At Quest Diagnostics, we are committed to providing you with results and insights to support your clinical decisions.
Date: 09/2024
Contributor(s): Kenneth French, Maeson Latsko, PhD
Additional Resources:
Podcast: Action from Insight: Tackling Insulin Resistance (18 min)
Webinar: Early Identification of Type 2 Diabetes Risk for the Primary Care Setting
Ordering information:
Insulin Resistance Panel with Score | Test Detail | Quest Diagnostics
Insulin Resistance Panel with Score | Test Summary | Quest Diagnostics
References:
Ward ZJ, Bleich SN, Cradock AL, et al. Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity. N Engl J Med. 2019;381(25):2440-2450. doi:10.1056/NEJMsa1909301 Abbasi F, Shiffman D, Tong CH, et al. Insulin resistance probability scores for apparently healthy individuals. J Endocr Soc. 2018;2(9):1050-1057. doi:10.1210/js.2018-00107 Bril F, McPhaul MJ, Kalavalapalli S, et al. Intact fasting insulin identifies nonalcoholic fatty liver disease in patients without diabetes. J Clin Endocrinol Metab. 2021;106(11):e4360-e4371. doi:10.1210/clinem/dgab417 Healy, M. By 2030, nearly half of all U.S. adults will be obese, experts predict. New York Times. https://www.latimes.com/science/story/2019-12-18/nearly-half-of-us-adults-will-be-obese-by-2030 Khan RMM, Chua ZJY, Tan JC, et al. From Pre-Diabetes to Diabetes: Diagnosis, Treatments and Translational Research. Medicina (Kaunas). 2019;55(9):546. doi:10.3390/medicina55090546 -
Despite advances in understanding the pathogenesis and prevention of atherosclerotic cardiovascular disease, coronary heart disease remains the leading cause of death in the United States. Apolipoprotein B (ApoB)—containing lipoproteins more closely identifies atherosclerosis and correlates to atherogenic particles in circulation.
This episode will:
Review the current state of cardiovascular risk assessmentDescribe lipoprotein anatomy and ApoBIdentify discordance between LDL cholesterol and ApoBDiscuss the guideline recommended clinical utility of ApoB in risk identificationTo learn more, please review the additional resources below for information on our cardiovascular, metabolic, endocrine, and wellness offerings, as well as educational resources and insights from our team of experts. At Quest Diagnostics, we are committed to providing you with results and insights to support your clinical decisions.
Date: 9/10/24
Contributor(s): Maeson Latsko, PhD
Additional Resources:
Quest Diagnostics Clinical Education Center [Link]
Ordering information: Apolipoprotein B | Test Detail | Quest Diagnostics
Apolipoprotein B | Test Summary | Quest Diagnostics
Apo B and cardiovascular risk | Quest Diagnostics | Quest Diagnostics
References:
Sniderman AD, Williams K, Contois JH, et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein b as markers of cardiovascular risk. Circ: Cardiovascular Quality and Outcomes. 2011;4(3):337-345. doi:10.1161/CIRCOUTCOMES.110.959247
Johannesen CDL, Langsted A, Nordestgaard BG, Mortensen MB. Excess apolipoprotein B and cardiovascular risk in women and men. J Am Coll Cardiol. 2024;83(23):2262-2273. doi:10.1016/j.jacc.2024.03.423
Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-e1143. doi:10.1161/CIR.0000000000000625
Contois JH, McConnell JP, Sethi AA, et al. Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clin Chem. 2009;55(3):407-419. doi:10.1373/clinchem.2008.118356
-
Despite advances in understanding the pathogenesis and prevention of atherosclerotic cardiovascular disease, coronary heart disease remains the leading cause of death in the United States. Lipoprotein (a), or Lp(a), is a particularly atherogenic type of lipoprotein, where excess levels significantly influence cardiovascular risk.
This episode will:
Review the significant cardiovascular implications of Lp(a) excessDescribe Lp(a) structureDiscuss how Lp(a) is measuredReview the treatment landscape for Lp(a)To learn more, please review the additional resources below for information on our cardiovascular, metabolic, endocrine, and wellness offerings, as well as educational resources and insights from our team of experts. At Quest Diagnostics, we are committed to providing you with results and insights to support your clinical decisions.
Date: 9/10/24
Contributor(s): Dr. Maeson Latsko
Additional Resources:
Ordering information: Lipoprotein (a) | Test Detail | Quest Diagnostics
Lipoprotein(a) | Test Summary | Quest Diagnostics
Quest Diagnostics Clinical Education Center [Link]
References:
Wilson DP, Jacobson TA, Jones PH, et al. Use of Lipoprotein(A) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. J Clin Lipidol. 2019;13(3):374-392. doi:10.1016/j.jacl.2019.04.010
Koschinsky ML, Bajaj A, Boffa MB, et al. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. J Clin Lipidol. 2024;18(3):e308-e319. doi:10.1016/j.jacl.2024.03.001
-
Hypogonadism is a common condition in the male population, impacting approximately 35% of men over 45 years of age. Today’s episode is with Quest Diagnostics experts Dr Sanjay Dixit, MD, medical director, and Maeson Latsko, PhD, clinical specialist.
This episode will:
Review the clinical and biochemical changes seen in male patients with hypogonadism (1:20)Discuss the guideline-recommended methodologies for testosterone analysis (3:24)Learn how to delineate between primary and secondary hypogonadism (7:38)To learn more, please view the additional resources below for information on our cardiovascular, metabolic, endocrine, and wellness offerings as well as educational resources and insights from our team of experts. At Quest Diagnostics, we are committed to providing you with results and insights to support your clinical decisions.
Date: May 3, 2024
Contributor(s): Dr. Sanjay Dixit, MD, Maeson Latsko, PhD
Additional Resources:
Quest Diagnostics Clinical Education Center
Quest Diagnostics Hypogonadism FAQs
Clinical Focus: Hypogonadism and Low Testosterone in Men
Adult Male Hypogonadism Diagnostic Algorithm
References See Quest Diagnostics Clinical Education Center
-
An estimated 20 million Americans have some form of thyroid disease, and up to 60% of them are unaware of their condition. Today’s episode is with Quest Diagnostics experts Dr Sanjay Dixit, MD, medical director, and Sarah Walsh, PA-C, CLS, clinical specialist.
This episode will:
Identify common signs and symptoms of thyroid dysfunctionIdentify lab recommendations to support the diagnosis of hypo- and hyperthyroidismDiscuss the association between cardiometabolic conditions and thyroid dysfunctionTo learn more, please review the additional resources below for information on our cardiovascular, metabolic, endocrine and wellness offerings, as well as educational resources and insights from our team of experts. At Quest Diagnostics, we are committed to providing you with results and insights to support your clinical decisions.
Date: 4/18/2024
Contributor(s): Dr. Sanjay Dixit, MD, Sarah Walsh, PA-C, CLS
Additional Resources:
Quest Diagnostics Clinical Education Center
Quest Diagnostics Thyroid Disorders
Clinical Focus: Thyroid Dysfunction in Nonpregnant Adults
Testing Algorithm for Thyroid Dysfunction in Nonpregnant Adults
References See Quest Diagnostics Clinical Education Center
-
Polycystic Ovary Syndrome (PCOS) is one of the most common endocrine diagnoses for reproductive-aged women and carries lifelong cardiometabolic risk. Today’s episode is with Quest Diagnostics experts Dr Sanjay Dixit, MD, medical director, and Sarah Walsh, PA-C, CLS, clinical specialist.
This episode will:
Review the diagnostic criteria for PCOS (2:00)Identify lab recommendations to support the diagnosis of PCOS (6:00)Discuss associated cardiometabolic conditions and how to screen and monitor for these conditions (14:45)To learn more, please review the additional resources below for information on our cardiovascular, metabolic, endocrine, and wellness offerings as well as educational resources and insights from our team of experts. At Quest Diagnostics, we are committed to providing you with results and insights to support your clinical decisions.
Date recorded: 4/9/2024
Contributor(s): Dr. Sanjay Dixit, MD, Sarah Walsh, PA-C, CLS
Additional Resources:
Quest Diagnostics Polycystic ovary syndromeClinical Focus: Polycystic Ovary Syndrome Polycystic Ovary Syndrome (PCOS) Diagnostic AlgorithmLaboratory Testing in the Differential Diagnosis of PCOS and NCCAHReferences See Quest Diagnostics Clinical Education Center
